Multiple sclerosis and related disorders · 2026
Epidemiology, diagnosis and outcomes of acquired demyelinating syndromes in children: A Czech perspective.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Toman Tomáš, Svěráková Anna, Čapek Václav, Hanáková Petra, Němcová Lucia, Píža Radim, Dostál Ondřej, Kašparová Hana, Ampapa Radek, Dvořáková Lenka, Procházková Lucie, Glombová Marie, Munzar Petr, Kočí Petra, Peřinová Zuzana, Matek Petr, Kršek Pavel, Libá Zuzana
Аннотация
BACKGROUND: Acquired demyelinating syndromes (ADS) include rare diagnoses of acute disseminated encephalomyelitis (ADEM), clinically isolated syndrome (CIS), multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Their characteristics in the Czech children are currently unknown.
OBJECTIVES: To identify the epidemiology, diagnosis, care management, and outcomes of Czech children with ADS.
METHODS: Data from a two-year prospective national multicenter study were analyzed. The incidence was calculated for the Czech population (< 18 years of age) per 100,000 per year sourcing data from the Czech Statistical Office.
RESULTS: Our study covered 84.1% of the population and included 81 patients. The overall incidence of pediatric ADS was 2.24/100,000 (95% confidence interval [CI] 1.76-2.79). In particular, POMS, CIS, ADEM, and NMOSD had an incidence of 1.19 (0.85-1.62); 0.7 (0.35-1.33); 0.32 (0.16-0.57); and 0.03 (0.0007-0.16), respectively. Myelin oligodendrocyte glycoprotein (MOG) antibodies were present in 19.8% of all patients. Age was associated with diagnoses, MOG antibodies and preceding infections. After the first ADS episode, 6.3% of the children remained severely affected.
CONCLUSION: This first comprehensive analysis of pediatric ADS in the Czech Republic provided unique data on ADS incidence, identified a significant proportion of POMS, and highlighted challenges in diagnosis and care.
OBJECTIVES: To identify the epidemiology, diagnosis, care management, and outcomes of Czech children with ADS.
METHODS: Data from a two-year prospective national multicenter study were analyzed. The incidence was calculated for the Czech population (< 18 years of age) per 100,000 per year sourcing data from the Czech Statistical Office.
RESULTS: Our study covered 84.1% of the population and included 81 patients. The overall incidence of pediatric ADS was 2.24/100,000 (95% confidence interval [CI] 1.76-2.79). In particular, POMS, CIS, ADEM, and NMOSD had an incidence of 1.19 (0.85-1.62); 0.7 (0.35-1.33); 0.32 (0.16-0.57); and 0.03 (0.0007-0.16), respectively. Myelin oligodendrocyte glycoprotein (MOG) antibodies were present in 19.8% of all patients. Age was associated with diagnoses, MOG antibodies and preceding infections. After the first ADS episode, 6.3% of the children remained severely affected.
CONCLUSION: This first comprehensive analysis of pediatric ADS in the Czech Republic provided unique data on ADS incidence, identified a significant proportion of POMS, and highlighted challenges in diagnosis and care.